Corcept Therapeutics (CORT) Cash & Equivalents (2010 - 2026)

Corcept Therapeutics (CORT) has 17 years of Cash & Equivalents data on file, last reported at $108.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 21.06% year-over-year to $108.7 million; the trailing twelve-month figure through Mar 2026 stood at $108.7 million (up 21.06% YoY), and the FY2025 full-year result was $120.5 million, down 5.62% from the prior year.
• Cash & Equivalents retreated to $108.7 million in Q1 2026, from $120.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $299.9 million in Q1 2023 to a low of $35.3 million in Q2 2022.
• A 5-year average of $119.0 million and a median of $120.5 million in 2025 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents slumped 62.96% in 2022 and soared 387.68% in 2023, its largest moves.
• Tracing CORT's Cash & Equivalents over 5 years: stood at $66.3 million in 2022, then soared by 104.36% to $135.6 million in 2023, then retreated by 5.82% to $127.7 million in 2024, then decreased by 5.62% to $120.5 million in 2025, then decreased by 9.76% to $108.7 million in 2026.
• Business Quant data shows CORT's Cash & Equivalents at $108.7 million in Q1 2026, $120.5 million in Q4 2025, and $125.1 million in Q3 2025.